Perspective Therapeutics (NYSEAMERICAN:CATX) Reaches New 12-Month High at $1.90

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reached a new 52-week high on Wednesday . The company traded as high as 1.90 and last traded at 1.84, with a volume of 3917500 shares changing hands. The stock had previously closed at 1.83.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on CATX shares. B. Riley upped their price target on Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Lifesci Capital reiterated an “outperform” rating on shares of Perspective Therapeutics in a report on Monday. Oppenheimer restated an “outperform” rating and set a $1.50 price target (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. Finally, Cantor Fitzgerald started coverage on shares of Perspective Therapeutics in a research report on Thursday. They issued an “overweight” rating for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus price target of 1.53.

Perspective Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07. The company has a market capitalization of $1.06 billion, a P/E ratio of -18.00 and a beta of 1.43.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Perspective Therapeutics stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at 110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.52% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bleakley Financial Group LLC bought a new position in Perspective Therapeutics in the 1st quarter worth approximately $40,000. RIA Advisory Group LLC lifted its position in shares of Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock worth $127,000 after acquiring an additional 99,293 shares in the last quarter. ZWJ Investment Counsel Inc. bought a new position in shares of Perspective Therapeutics in the first quarter worth $26,000. Simplicity Wealth LLC purchased a new position in shares of Perspective Therapeutics in the first quarter valued at $40,000. Finally, Taylor & Morgan Wealth Management LLC raised its stake in shares of Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after purchasing an additional 50,000 shares during the period. Institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.